AstraZeneca

Goal disorientation and lack of vision

Biotech

AstraZeneca amyloidosis drug fails to reduce mortality in ph. 3

Plans for an amyloidosis blockbuster look further out of reach after the anti-fibril antibody failed to reduce deaths and hospitalizations.

James Waldron Jul 16, 2025 4:28am

bet poker chips las vegas betting gamble

AstraZeneca’s $1.3B hypertension med bet pays off with ph. 3 win

Jul 14, 2025 4:09am

Glowing puzzle piece fitting into puzzle

Eolas regains opioid use disorder drug abandoned by AstraZeneca

Jul 10, 2025 9:33am

reshuffle pipeline target reorganize shift change

AstraZeneca’s Alexion pens $825M AAV capsid pact with JCR

Jul 9, 2025 4:52am

Horseshoe magnet attracting metallic pawn people

Biotech shares first data for in vivo CAR-T that attracted AZ

Jul 7, 2025 2:27pm

Question

Fierce Pharma

Summit in high-stakes deal talks with AstraZeneca: Bloomberg

Jul 7, 2025 10:45am